## Attention: Medicaid Fee- for- Service Providers Dispense Brand Name Drug when Less Expensive than Generic Program

Effective November 29, 2012, the following changes will be made to the Dispense Brand Name Drug when Less Expensive than Generic Program:

- Arixtra will be removed from the Program.
- Actos, Actoplus Met and Diovan HCT will be added to the Program.

In conformance with State Education Law which intends that patients receive the lower cost alternative, brand name drugs included in this program:

- Do not require 'Dispense as Written' (DAW) or 'Brand Medically Necessary' on the prescription.
- Have a generic copayment.
- Are paid at the Brand Name Drug reimbursement rate or usual and customary price, whichever is lower (SMAC/FUL are not applied).
- Do not require a new prescription if the drug is removed from this program.

## **IMPORTANT BILLING INFORMATION**

Prescription claims submitted to the Medicaid program **do not require** the submission of Dispense As Written/Product Selection Code of '1'; and **Pharmacies can submit any valid NCPDP field (408-D8) value.** 

Geodon
Epivir
Kadian
Lexapro
Lovenox
Nasacort AQ
Symbyax
Valtrex
Ziagen tablet

## Current list of Brand Name Drugs included in this program\* (Date Revised 10/17/12):

\*List is subject to change

Please keep in mind that drugs in this program may be subject to prior authorization requirements of other pharmacy programs, promoting the use of the most cost-effective product.